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Abstract
Background: Previous studies comparing levosimendan vs. dobutamine have revealed that 
levosimendan is better in relieving symptoms. Echocardiographic studies have been done using 
second measurements immediately following a dobutamine infusion or while it was still being 
administered. The aim of our study was assessment of sustained effects of 24 h levosimendan 
and dobutamine infusions on left ventricular systolic functions.
Methods: A total of 61 patients with acutely decompensated heart failure with New York 
Heart Association (NYHA) class III or IV symptoms were randomized to receive either levosi-
mendan or dobutamine 2:1 in an open label fashion. Before and 5 days after the initiation of 
infusions, functional class was assessed, N-terminal prohormone of B-type natriuretic peptide 
(NT-proBNP) levels and left ventricular ejection fraction (LVEF), mitral inflow peak E and 
A wave velocity, and E/A ratios were measured; using tissue Doppler imaging, isovolumic 
myocardial acceleration (IVA), peak myocardial velocity during isovolumic contraction (IVV), 
peak systolic velocity during ejection period (Sa), early (E’) and late (A’) diastolic velocities, 
and E’/A’ and E/E’ ratios were measured.
Results: The NYHA class improved in both groups, but improvements were prominent in 
the levosimendan group. NT-proBNP levels were significantly reduced in the levosimendan 
group. Improvements in LVEF and diastolic indices were significant in the levosimendan 
group. Tissue Doppler-derived systolic indices of IVV and IVA increased significantly in the 
levosimendan group.
Conclusions: Improvements in left ventricular systolic and diastolic functions continue after 
a levosimendan infusion. (Cardiol J 2015; 22, 1: 87–93)
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Introduction
Heart failure (HF) patients are generally trea-
ted with diuretics, vasodilators, and beta-blockers 
in the long term. Positive intravenous inotropes 
are considered for therapy when the exacerbation 
of HF is accompanied by evidence of low cardiac 
output, such as hypotension and oliguria; however, 
their long-term usage is limited due to the high 
rate of mortality [1].
Levosimendan is a positive inotropic drug with 
a vasodilator effect. It exerts positive inotropic ef-
fects by binding cardiac troponin C and sensitizing 
cardiac myofilaments to calcium without increasing 
intracellular calcium concentrations [2]. The active 
metabolite of levosimendan peaks approximately 
3 days after the start of drug infusion and has a half-
life of approximately 80 h; thus the drug’s action is 
expected to last for 2 weeks [3]. Dobutamine has 
a serum half-life of 2 min and has no known active 
metabolite [4].
Isovolumic acceleration (IVA) is a novel tissue 
Doppler parameter for the assessment of systolic 
functions of both left and right ventricles [5, 6]. 
IVA reflects the acceleration of the myocardium at 
the very beginning of the isovolumic contraction 
velocity (IVV) period. IVA remains unaffected by 
the changes in the preload and afterload within the 
physiological range [5, 7]. It can detect even small 
changes in contractile function and is well corre-
lated with the invasive or noninvasive measures 
of left ventricle (LV) dp/dt [5, 8].
In the present study, we aimed to determine 
whether levosimendan and dobutamine infusions 
have any ongoing effects on LV systolic and di-
astolic functions using conventional echocardio-
graphic and tissue Doppler imaging (TDI)-derived 
parameters after the completion of infusions in 
acute decompensated HF patients.
Methods
Study design and patient population
Seventy-five consecutive patients in sinus 
rhythm with severe LV systolic dysfunction (ejec-
tion fraction [EF] < 35%) who had been hospital-
ized due to acutely decompensated HF with New 
York Heart Association (NYHA) class III or IV 
symptoms despite medical therapy (including diu-
retics, ACE inhibitors/ARBs, beta-blockers, and 
spironolactone) were decided to be administered 
inotropic therapy and evaluated. The exclusion 
criteria were: patients who were younger than 
18 years or older than 80 years, in cardiogenic shock, 
had supine systolic blood pressure < 85 mm Hg, 
heart rate > 135 bpm, serious arrhythmias, hepatic 
or renal impairment (creatinine > 5 mg/dL), HF 
due to restrictive or hypertrophic cardiomyopathy, 
severe valvular disease except functional mitral 
regurgitation, chronic obstructive pulmonary dis-
ease, a levosimendan infusion within 6 months, 
recent myocardial infarction (< 2 months) or acute 
coronary syndromes, acute or chronic infectious or 
inflammatory disease, or poor echocardiographic 
image quality. The study protocol was approved by 
the institutional Ethics Committee, and written in-
formed consent was obtained before randomization.
Five patients with poor echocardiographic im-
age quality received inotropic infusions but were 
not included in the study. Patients were randomized 
to receive either levosimendan (n = 47) or dobu-
tamine (n = 23) 2:1 in an open label fashion. 
Levosimendan was administered for 24 h, and 
a 12 mg/kg/min loading dose was given for 10 min 
to 22 patients whose systolic blood pressure was 
> 90 mm Hg. All patients received a continuous 
infusion of 0.1 mg/kg/min administered for 50 min 
and up titrated to an infusion rate of 0.2 mg/kg/ 
/min if tolerated. Dobutamine was infused for 24 h 
at an initial dose of 5 mg/kg/min; up titration of 
the dobutamine dose was left for the physician to 
decide. Atrial fibrillation occurred in 1 patient in 
the levosimendan group; 6 patients in the levosi-
mendan group and 2 patients in the dobutamine 
group whose functional class was improved refused 
to stay in hospital for 5 days or come to hospital 
again on the 5th day for echocardiographic measure-
ments and thus were discharged and not included in 
the study. A total of 61 patients data who received 
levosimendan (n = 40) or dobutamine (n = 21) 
were analyzed (Fig. 1).
Conventional echocardiographic examination
Echocardiographic examinations were con-
ducted before drug administration and 5 days after 
the initiation of treatment. All of the transthoracic 
echocardiographic examinations were performed 
using the GE vivid S6 Vingmed system 5 (Norway, 
Horten) equipped with 2.5–4 MHz transducers. All 
of the patients were examined in the left lateral 
and supine positions with 2-dimensional, M-mode, 
pulsed, and color flow Doppler echocardiography. 
A single lead electrocardiogram was recorded 
continuously. An average of at least 5 cardiac 
cycles were obtained for all measurements. Echo-
cardiographic analyses were performed by an 
experienced echocardiography specialist who was 
blinded to all data.
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M-mode measurements and conventional 
Doppler echocardiographic examinations were 
performed based on the criteria of the American 
Society of Echocardiography and European Society 
of Echocardiography guidelines [9]. Left atrial, LV 
end-systolic, and end-diastolic dimensions were 
measured in the parasternal long-axis views. LVEF 
was estimated by the Simpson’s rule. The mitral 
inflow peak velocity during early filling (E) and late 
filling from atrial contraction (A) as well as the E/A 
ratio were measured.
Tissue Doppler imaging
Doppler tissue echocardiography was per-
formed using transducer frequencies between 
3.5 to 4.0 MHz, by adjusting the spectral pulsed 
Doppler signal filters until a Nyquist limit of 15– 
–20 cm/s was reached, and using the minimal optimal 
gain. Five consecutive cycles were recorded with 
a frame rate greater than 150 fps. The monitor 
sweep speed was set at 50–100 mm/s to optimize 
the spectral display of myocardial velocities. Every 
effort was made to align the pulsed wave cursor so 
that the Doppler angle of incidence was as close to 
0 as possible to the direction of these walls. In the 
apical 4-chamber view, the pulsed Doppler sample 
volume was subsequently placed at the level of LV 
lateral and septal basal wall at end-expiration [10].
Peak myocardial IVV, peak myocardial sys-
tolic velocity (Sm), peak early and late diastolic 
velocities (E’ and A’), and IVA time were meas-
ured. Myocardial acceleration during IVA was 
defined as the ratio of IVV divided by the ac-
celeration time. For intraobserver variability of 
the Sm, IVV and IVA obtained from 10 random 
patients measured repeatedly within intervals of 
a few minutes. Intraobserver variability of Sm, IVV, 
and IVA was found to be r = 0.98, r = 0.97 and 
r = 0.97, respectively.
Blood samples for analyses of natriuretic pep-
tide levels were drawn from patients in the supine 
position before the echocardiographic examina-
tions (baseline and after 5 days) using Elecsys 
N-terminal prohormone of B-type natriuretic pep-
tide (NT-proBNP) kits (Roche diagnostics, Man-
nheim, Germany) by an observer who was blinded 
to patient identity and treatments.
Statistical analysis
Statistical analyses were performed using the 
SPSS software version 17.0 for Windows (SPSS 
Inc., Chicago, Illinois, USA). The variables were 
investigated using visual (histograms, probabil-
ity plots) and analytical methods (Kolmogorov-
-Smirnov/Shapiro-Wilk’s test) to determine the 
normal distribution. Descriptive analyses are 
presented using means and standard deviations 
or median and the interquartile range (range from 
the 25th to the 75th percentile). The categorical 
variables are expressed as numbers and percent-
ages. Numerical variables were compared using the 
Mann-Whitney U or Student’s t-test. Categorical 
data were compared with the c2 test. The paired 
Student’s t-test or Wilcoxon test were used to 
compare the measurements at two time points. 
Intraobserver agreement was assessed with Spear-
man’s correlation coefficients, and a p value < 0.05 
was considered significant.
Results
Patients randomized to either the levosi-
mendan or dobutamine group were similar with 
respect to pretreatment characteristics and con-
comitant medications (Table 1). As indicated in 
Table 2, the levosimendan group was associated 
with a significant reduction in NT-proBNP levels 
and a significant improvement in the NYHA class. 
In the dobutamine group, the NYHA class signifi-
cantly improved, but the reduction in NT-proBNP 
levels was not significant. The improvement 
in the NYHA class was more prominent in the 
Figure 1. Patient disposition.
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levosimendan group (p < 0.001 vs. p = 0.003). 
Systolic and diastolic blood pressures, heartbeat, 
creatinine levels, and hematocrit percentages did 
not significantly change in the levosimendan and 
dobutamine groups.
Conventional echocardiographic findings
In the group treated with levosimendan, LV 
systolic and diastolic diameters and left atrial diam-
eter significantly reduced and LVEF significantly 
improved (Table 3). In the dobutamine group, none 
Table 2. Clinical and laboratory parameters before and after treatment in the levosimendan and  
dobutamine groups.
Variable Levosimendan P Dobutamine P
Before After Before After
SBP [mm Hg] 116.5 ± 22.9 110.1 ± 17.6 0.057 115.4 ± 23.0 110.4 ± 14.9 0.325
DBP [mm Hg] 68.0 ± 12.3 65.5 ± 11.6 0.207 65.2 ± 12.0 65.1 ± 11.3 0.971
Heart rate [bpm] 77 (66–83) 77 (67–83) 0.675 75 (66–82) 77 (69–82) 0.955
Creatinine [mg/dL] 1.2 (1.0–1.4) 1.3 (1.0–1.5) 0.992 1.3 (1.1–1.8) 1.5 (1.1–1.8) 0.582









NYHA class 3.6 ± 0.5 2.2 ± 0.7 < 0.001 3.7 ± 0.5 3.1 ± 0.7 0.003
Hematocrit [%] 37.7 ± 5.0 37.0 ± 5.7 0.200 36.8 ± 5.9 35.0 ± 5.1 0.081
Values are presented as mean ± standard deviation or median (interquartile range); SBP — systolic blood pressure; DBP — diastolic blood 
pressure; NT-proBNP — N-terminal prohormone of B-type natriuretic peptide; NYHA — New York Heart Association
Table 1. Baseline characteristics of the patients according to treatment group.
Variable Levosimendan (n = 40) Dobutamine (n = 21) P 
Age [years] 59.7 ± 11.2 63.8 ± 9.0 0.151
Gender, men 32 (80%) 18 (85.7%) 0.430
Body mass index [kg/m2] 27.9 ± 4.6 27.6 ± 5.8 0.864
NT-proBNP [pg/mL] 7099 (2754–12100) 4130 (2168–9060) 0.333
Creatinine [mg/dL] 1.2 (1.0–1.4) 1.3 (1.1–1.8) 0.289
Systolic blood pressure [mm Hg] 116.5 ± 22.9 115.4 ± 23.0 0.863
Diastolic blood pressure [mm Hg] 68.0 ± 12.3 65.2 ± 12.0 0.395
Heart rate [bpm] 77 (66–83) 75 (66–82) 0.790
Hypertension 21 (52.5%) 9 (42.9%) 0.474
Diabetes mellitus 23 (57.5%) 11 (52.4%) 0.702
Hyperlipidemia 14 (35%) 6 (28.6%) 0.611
Heart failure etiology, ischemic 32 (80%) 17 (81%) 0.606
NYHA class IV 25 (62.5%) 15 (71.4%) 0.486
Left ventricular ejection fraction [%] 24.5 ± 5.4 25.7 ± 5.6 0.412
Medication:
ACEI 29 (72.5%) 15 (71.4%) 0.286
Angiotensin II blockers 5 (12.5%) 2 (9.5%) 0.544
Beta-blockers 34 (85%) 17 (81%) 0.473
Diuretic 40 (100%) 21 (100%)
Spironolactone 25 (62.5%) 13 (61.9%) 0.964
Statin 7 (17.5%) 4 (19%) 0.570
Aspirin 30 (75%) 15 (71.4%) 0.763
Clopidogrel 8 (20%) 7 (33.3%) 0.251
Nitrate 13 (32.5%) 6 (28.6%) 0.753
Values are presented as mean ± standard deviation, median (interquartile range) or number or percentage of patients; NT-proBNP — N-termi-
nal prohormone of B-type natriuretic peptide; NYHA — New York Heart Association; ACEI — angiotensin-converting enzyme inhibitors 
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of these parameters changed significantly. The mi-
tral E velocity and E/A ratio significantly increased, 
and the mitral A velocity and deceleration time 
significantly increased in levosimendan-treated 
patients, but none of these parameters significantly 
changed in dobutamine-treated patients (Table 3).
Tissue Doppler findings
In the levosimendan group, E’, A’, Sa, IVV, and 
IVA parameters significantly increased, E/E’ signi-
ficantly decreased, and the decrease in E’/A’ was 
not significant. None of these parameters changed 
significantly in the dobutamine group (Table 3).
Discussion
The present study indicates that a 24-h infu-
sion of levosimendan is better than dobutamine in 
terms of improving LV systolic and diastolic func-
tions based on both conventional echocardiography 
parameters and TDI-derived parameters as well 
as decreasing NT-proBNP levels 5 days after the 
initiation of treatment.
Levosimendan has a half-life of approximately 
1 h [11], but levosimendan’s active metabolites are 
expected to sustain its effects up to 2 weeks [3]. 
Dobutamine has a short half-life and has no known 
active metabolite [4], but it has been suggested 
that after short-term infusion, the benefit can last 
for 30 days or more; this phenomenon is called 
the “dobutamine holiday” [12]. The persistence of 
clinical benefits after dobutamine infusion has been 
attributed to sustained improvement in myocardial 
contractility [12], a training-like effect on skeletal 
muscles [13], and an improvement in vascular 
endothelial function [14].
Studies comparing levosimendan and dobu-
tamine using echocardiographic parameters gen-
erally performed a second echocardiographic 
examination just after inotrope infusions [15–17]. 
We performed echocardiographic measurements 
5 days after the initiation of infusions to determine 
whether the favorable effects of the levosimendan 
and dobutamine continue following infusions.
Levosimendan exerts its positive inotropic 
effect without impairing diastolic relaxation [18], 
Table 3. Echocardiographic parameters before and after treatment in the levosimendan and  
dobutamine groups.
Variable Levosimendan P Dobutamine P
Before After Before After
Two-dimensional, M-mode, PW Doppler measurements
LVEDd [cm] 6.4 ± 0.8 6.3 ± 0.8 < 0.001 6.3 ± 0.7 6.3 ± 0.8 0.896
LVESd [cm] 5.5 ± 0.8 5.3 ± 0.9 0.003 5.3 ± 0.7 5.3 ± 0.8 0.613
IVS [cm] 0.99 ± 0.18 1.00 ± 0.15 0.501 0.98 ± 0.2 0.96 ± 0.18 0.408
PW [cm] 0.97 ± 0.16 0.97 ± 0.14 0.711 0.94 ± 0.2 0.93 ± 0.23 0.607
LVEF [%] 24.8 ± 5.4 30.2 ± 4.5 < 0.001 26.1 ± 5.5 27.4 ± 5.2 0.107
LA diameter [cm] 4.7 ± 0.5 4.6 ± 0.5 0.004 4.9 ± 0.7 4.8 ± 0.5 0.363
E [cm/s] 95.9 ± 27.7 88.8 ± 23.6 < 0.001 98.7 ± 24.0 97.5 ± 22.7 0.008
A [cm/s] 42.1 ± 15.0 44.4 ± 15.2 < 0.001 39.6 ± 11.2 39.8 ± 11.8 0.168
DT [ms] 150.9 ± 36.4 155.4 ± 37.5 < 0.001 142.8 ± 27.2 142.2 ± 27.5 0.624
E/A 2.5 ± 1.0 2.2 ± 0.8 < 0.001 2.6 ± 0.7 2.5 ± 0.7 0.013
Tissue Doppler
E’ [cm/s] 5.1 ± 1.5 6.0 ± 1.8 < 0.001 5.01 ± 1.3 5.2 ± 1.3 0.031
A’ [cm/s] 3.8 ± 1.1 4.6 ± 1.6 < 0.001 4.1 ± 0.9 4.2 ± 0.9 0.083
E’/A’ 1.5 ± 0.7 1.4 ± 0.6 0.580 1.3 ± 0.3 1.3 ± 0.4 0.223
E/E’ 20.6 ± 9.3 14.9 ± 5.2 < 0.001 20.8 ± 7.0 20.1 ± 6.9 0.006
Sa [cm/s] 4.0 ± 0.9 4.6 ± 1.0 < 0.001 4.1 ± 0.08 4.2 ± 0.7 0.264
IVV [cm/s] 3.6 ± 0.7 4.2 ± 0.8 < 0.001 3.7 ± 0.9 3.8 ± 0.8 0.100
IVA (m/s2) 1.1 ± 0.2 1.4 ± 0.3 < 0.001 1.1 ± 0.4 1.2 ± 0.4 0.088
Values are presented as mean ± standard deviation; LVEDd — left ventricular end-diastolic diameter; LVESd — left ventricular end-systolic 
diameter; IVS — interventricular septum; PW — posterior wall; LVEF — left ventricular ejection fraction; LA — left atrium; DT — deceleration 
time; E — mitral inflow peak early diastolic wave velocity; A — mitral inflow peak late diastolic wave velocity E’ — flow velocity of the early 
diastole using tissue Doppler echocardiography; A’ — flow velocity of the late diastole using tissue Doppler echocardiography; Sa — peak 
velocity of myocardial systolic wave; IVV — isovolumic velocity; IVA — isovolumic acceleration
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whereas dobutamine increases myocardial cyclic 
adenosine monophosphate (cAMP) by stimulating 
the beta-adrenoreceptors. Raised cAMP concen-
trations causes intracellular calcium to increase, 
which exacerbates diastolic dysfunction [1]. Paris-
sis et al. [19] showed that levosimendan infusion 
improved echocardiographic markers of abnormal 
LV diastolic function. Consistent with this study, 
in our study a levosimendan infusion lead to 
a significant increase in mitral A wave and decel-
eration time and a significant decrease in E/A and 
E/E’ ratios. Dobutamine infusion did not cause any 
significant change in diastolic function parameters.
In a study comparing the effect of levosi-
mendan and dobutamine infusion on left atrial func-
tions [20], levosimendan infusions improved dias-
tolic functions, decreased the E wave and E/A and 
E/E’ ratios and increased the A wave significantly. 
Dobutamine infusions improved only the E/E’ ratio. 
Duman et al. [21] also showed improvements in 
diastolic functions with levosimendan infusions, 
significant decreases in E/A and E/E’ ratios and 
an increase in the A wave, deceleration time, and 
isovolumic relaxation time. Dobutamine infusions 
did not cause any significant change.
Both levosimendan and dobutamine enhance 
LV systolic function. In studies comparing levo-
simendan and dobutamine, some showed signifi-
cant improvement in LVEF [15, 20, 21] both with 
levosimendan and dobutamine, but in a study in 
which patients were treated with carvedilol [17], 
the dobutamine group did not show an improve-
ment in LVEF. In our study, LVEF significantly 
improved in the levosimendan group, but not in 
the dobutamine group. We think there are two 
possible reasons for this finding. In our study, 81% 
of patients in the dobutamine group were on beta-
blocker therapy, and this might attenuate effects 
of dobutamine. The second possible explanation is 
that we evaluated echocardiographic parameters 
5 days after initiation of infusions, thus dobu-
tamine’s effects culminated and dobutamine did 
not have sustaining effects.
LVEF and Sm are indicators of systolic func-
tion, but they are affected by loading conditions. 
Decompensated HF patients commonly take 
a considerable amount of diuretics. The loading 
conditions of these patients are unstable. IVA is 
a novel tissue Doppler parameter. IVA remains 
unaffected by preload and afterload changes within 
the physiological range [5, 7]. It can detect even 
small changes in the contractile function and is well 
correlated with the invasive or noninvasive meas-
ures of LV dp/dt [5, 8]. This parameter has been 
successfully validated in clinical studies [22–24]. 
Improvements in IVA were significant for the le-
vosimendan group but not the dobutamine group in 
our study. The effects of dobutamine seem to cul-
minate directly following an infusion. Dobutamine 
also caused improvements in the NYHA class, but 
the prominent improvements in the NYHA class 
with levosimendan infusions can be explained by 
the ongoing effects of active metabolites.
In the SURVIVE trial [25], BNP levels marked-
ly decreased at day 1, both with levosimendan and 
dobutamine. After day 1, the BNP level remained 
low with levosimendan but rapidly increased with 
dobutamine and nearly returned baseline levels at 
day 5 in the SURVIVE trial. These results are con-
sistent with our study; the NT-proBNP reduction 
was significant in the levosimendan group but not 
in the dobutamine group. This can also be explained 
by the lack of extended effects of dobutamine.
Limitations of the study
The major limitation is the small size of our 
patient groups. Additionally, systolic function pa-
rameters were not compared with the parameters 
obtained from cardiac catheterization. New imag-
ing modalities to evaluate LV systolic and diastolic 
functions such as cardiac magnetic resonance imag-
ing and speckle tracking echocardiography were 
not used in our study.
Conclusions
Improvements in functional capacity and LV 
systolic and diastolic functions continue after 
levosimendan infusions but not after dobutamine 
infusions, as expressed by conventional echocar-
diographic and TDI-derived parameters in patients 
with acute decompensated HF.
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